Consequences of manganese administration for striatal dopamine and motor behavior in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed C57BL/6 mice

Human and Experimental Toxicology

Volumn 32, Issue 8, 2013, Pages 865-880

  Dodd, C A ^a   Bloomquist, J R ^b   Klein, B G ^c  

^a FORT VALLEY STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; basal ganglia; dopamine; Manganese; motor behavior; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; MANGANESE CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG EFFECT; FATIGUE; GRIP STRENGTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; REARING; SURVIVAL TIME; SWIMMING;

1-METHYL-4-PHENYL-1; 2; 3; 6-TETRAHYDROPYRIDINE; BASAL GANGLIA; DOPAMINE; MANGANESE; MOTOR BEHAVIOR; PARKINSON'S DISEASE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DRUG INTERACTIONS; MALE; MANGANESE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING;

MUS;

EID: 84879741694     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112469043     Document Type: Article

References (71)

1. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology. 2002 ; 23: 487-502
2. Schapira AH. Etiology and pathogenesis of Parkinson disease. Neurol Clin. 2009 ; 27: 583-603
3. Perl DP, Olanow CW. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol. 2007 ; 66: 675-682
4. Weiss B. Economic implications of manganese neurotoxicity. Neurotoxicology. 2006 ; 27: 362-368
5. Obeso JA, Rodriguez-Oroz MC, Lanciego JL, et al. How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci. 2004 ; 27: 125-127
6. Deng Y, Xu Z, Xu B, et al. The protective effect of riluzole on manganese caused disruption of glutamate- glutamine cycle in rats. Brain Res. 2009 ; 1289: 106-117
7. Erikson KM, Dorman DC, Lash LH, et al. Duration of airborne-manganese exposure in rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity. Neurotoxicology. 2008 ; 29: 377-385
8. Fitsanakis VA, Au C, Erikson KM, et al. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochem Int. 2006 ; 48: 426-433
9. Hamani C, Saint-Cyr JA, Fraser J, et al. The subthalamic nucleus in the context of movement disorders. Brain. 2004 ; 127: 4-20
10. Steigerwald F, Potter M,, Herzog J. Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. J Neurophysiol. 2008 ; 100: 2515-2524
11. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998 ; 44: S175 - S188
12. Gorell JM, Johnson CC,, Rybicki BA. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology. 1999 ; 20: 239-247
13. Zayed J, Ducic S,, Campanella G. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 1990 ; 17: 286-291
14. Racette BA, McGee-Minnich L,, Moerlein SM. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology. 2001 ; 56: 8-13
15. Finkelstein MM,, Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res. 2007 ; 104: 420-432
16. Stampfer MJ. Welding occupations and mortality from Parkinson's disease and other neurodegenerative diseases among United States men, 1985-1999. J Occup Environ Hyg. 2009 ; 6: 267-272
17. Park J, Yoo CI,, Sim CS. A retrospective cohort study of Parkinson's disease in Korean shipbuilders. Neurotoxicology. 2006 ; 27: 445-449
18. Witholt R, Gwiazda RH,, Smith DR. The neurobehavioral effects of subchronic manganese exposure in the presence and absence of pre-parkinsonism. Neurotoxicol Teratol. 2000 ; 22: 851-861
19. Takahashi RN, Rogerio R,, Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol. 1989 ; 66: 167-170
20. Rojas P,, Rios C. Short-term manganese pretreatment partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurochem Res. 1995 ; 20: 1217-1223
21. Sziraki I, Mohanakumar KP,, Rauhala P. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience. 1998 ; 85: 1101-1111
22. Schmidt N,, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm. 2001 ; 108: 1263-1282
23. Heikkila RE, Cabbat FS,, Manzino L. Effects of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology. 1984 ; 23: 711-713
24. Baek SY, Kim YH, Oh SO, et al. Manganese does not alter the severe neurotoxicity of MPTP. Hum Exp Toxicol. 2007 ; 26: 203-211
25. Baek SY, Lee MJ,, Jung HS. Effect of manganese exposure on MPTP neurotoxicities. Neurotoxicology. 2003 ; 24: 657-665
26. Goodrick CL. Life-span and the inheritance of longevity of inbred mice. J Gerontol. 1975 ; 30: 257-263
27. Guide for the care and use of laboratory animals. 8 th ed. Washington, DC, USA: The National Academies Press, 2011. Washington, DC, USA: The National Academies Press ; 2011:
28. Dodd CA, Ward DL,, Klein BG. Basal ganglia accumulation and motor assessment following manganese chloride exposure in the C57BL/6 mouse. Int J Toxicol. 2005 ; 24: 389-397
29. Milatovic D, Zaja-Milatovic S,, Gupta RC. Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol. 2009 ; 240: 219-225
30. Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004 ; 24 (20). 4778-4786
31. Hickey MA, Gallant K, Gross GG, et al. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis. 2005 ; 20 (1). 1-11
32. Haenggeli C, Julien JP, Mosley RL, et al. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis. 2007 ; 26 (1). 146-152
33. Jussofie A, Lojewski J,, Hiemke C. Simultaneous automated determination of catecholamines, serotonin, and their metabolites in brain tissue by HPLC and electrochemical detection. J Liquid Chromatogr. 1993 ; 16: 447-463
34. Dean AM,, Voss DT Design and analysis of experiments. New York: Springer-Verlag ; 1999:
35. Westfall PH, Tobias RD, Wolfinger RD Multiple comparisons and multiple tests using SAS. 2 nd ed. Cary, NC, USA: SAS Institute Inc., 2011. Cary, NC, USA: SAS Institute Inc ; 2011:
36. Gianutsos G, Seltzer MD,, Saymeh R. Brain manganese accumulation following systemic administration of different forms. Arch Toxicol. 1985 ; 57: 272-275
37. Normandin L, Panisset M,, Zayed J. Manganese distribution in the brain and neurobehavioral changes following inhalation exposure of rats to three chemical forms of manganese. Neurotoxicology. 2004 ; 25: 433-441
38. Roels H, Meiers G,, Delos M. Influence of the route of administration and the chemical form (MnCl2, MnO2) on the absorption and cerebral distribution of manganese in rats. Arch Toxicol. 1997 ; 71: 223-230
39. Dorman DC, Struve MF,, James RA. Influence of particle solubility on the delivery of inhaled manganese to the rat brain: manganese sulfate and manganese tetroxide pharmacokinetics following repeated (14-day) exposure. Toxicol Appl Pharmacol. 2001 ; 170: 79-87
40. Dickerson RN. Manganese intoxication and parenteral nutrition. Nutrition. 2001 ; 17: 689-693
41. Komaki H, Maisawa S,, Sugai K. Tremor and seizures associated with chronic manganese intoxication. Brain Dev. 1999 ; 21: 122-124
42. Masumoto K, Suita S, Taguchi T, et al. Manganese intoxication during intermittent parenteral nutrition: report of two cases. J Parenter Enteral Nutr. 2001 ; 25: 95-99
43. Thiruchelvam M, Richfield EK, Baggs RB. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci. 2000 ; 20: 9207-9214
44. Bonuccelli U, Garant D,, Fariello R. The acute convulsant effect of MPTP is dependent on intracerebral MPP+. Neurosci Lett. 1991 ; 124: 22-26
45. Miller DB, Reinhard JF, Daniels AJ. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J Neurochem. 1991 ; 57: 541-549
46. Yurek DM, Deutch AY,, Roth RH. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 1989 ; 497: 250-259
47. Chen P, Chen Z, Li A, et al. Catalytic metalloporphyrin protects against paraquat neurotoxicity in vivo. Biomed Environ Sci. 2008 ; 21: 233-238
48. Nowak P, Bojanek K,, Szkilnik R. Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. Neurotox Res. 2011 ; 19: 536-543
49. Thiruchelvam M, Brockel BJ,, Richfield EK. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 2000 ; 873: 225-234
50. Calabresi P, Ammassari-Teule M,, Gubellini P. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication. Neurobiol Dis. 2001 ; 8: 419-432
51. Nam J,, Kim K. Abnormal motor function and the expression of striatal dopamine D2 receptors in manganese-treated mice. Biol Pharm Bull. 2008 ; 31: 1894-1897
52. Guilarte TR, Chen MK, McGlothan JL, et al. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006 ; 202: 381-390
53. Stanwood GD, Leitch DB,, Savchenko V. Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem. 2009 ; 110: 378-389
54. Gwiazda RH, Lee D,, Sheridan J. Low cumulative manganese exposure affects striatal GABA but not dopamine. Neurotoxicology. 2002 ; 23: 69-76
55. Struve MF, McManus BE,, Wong BA. Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. Am J Ind Med. 2007 ; 50: 772-778
56. Luchtman DW, Shao D,, Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav. 2009 ; 98: 130-138
57. Loschmann PA, Lange KW,, Wachtel H. MPTP-induced degeneration: interference with glutamatergic toxicity. J Neural Transm Suppl. 1994 ; 43: 133-143
58. Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain. 2007 ; 130: 2129-2145
59. Aschner M, Erikson KM, Dorman DC. Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol. 2005 ; 35: 1-32
60. Aschner M, Vrana KE,, Zheng W. Manganese uptake and distribution in the central nervous system (CNS). Neurotoxicology. 1999 ; 20: 173-180
61. Sotogaku N, Oku N, Takeda A. Manganese concentration in mouse brain after intravenous injection. J Neurosci Res. 2000 ; 61: 350-356
62. Rios C, Alvarez-Vega R, Rojas P. Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacol Toxicol. 1995 ; 76: 348-352
63. Tarohda T, Ishida Y,, Kawai K. Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal Bioanal Chem. 2005 ; 383: 224-234
64. dos Santos AP, Milatovic D,, Au C. Rat brain endothelial cells are a target of manganese toxicity. Brain Res. 2010 ; 1326: 152-161
65. Anderson JG, Cooney PT,, Erikson KM. Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol. 2007 ; 23: 179-184
66. Erikson KM, John CE,, Jones SR. Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. Environ Toxicolo Pharmacol. 2005 ; 20: 390-394
67. McDougall SA, Reichel CM,, Farley CM. Postnatal manganese exposure alters dopamine transporter function in adult rats: Potential impact on nonassociative and associative processes. Neuroscience. 2008 ; 154: 848-860
68. Grunecker B, Kaltwasser SF,, Peterse Y. Fractionated manganese injections: effects on MRI contrast enhancement and physiological measures in C57BL/6 mice. NMR Biomed. 2010 ; 23: 913-921
69. Martinez HJ, Castro-Caraballo F,, Arrieta A. Spontaneous motor activity and brain catecholamines in C57BL/6 and albino mice treated with manganese. Invest Clin. 2004 ; 45: 3-15
70. Moreno JA, Yeomans EC,, Streifel KM. Age-dependent susceptibility to manganese-induced neurological dysfunction. Toxicol Sci. 2009 ; 112: 394-404
71. Kern CH, Stanwood GD,, Smith DR. Preweaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levels. Synapse. 2010 ; 64: 363-378